3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Atomic Benchmarks for H+,K+-ATPase Inhibition

Executive Summary. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) is a potent and selective H+,K+-ATPase inhibitor with an IC50 of 5.8 μM in enzyme assays and 0.16 μM for histamine-stimulated gastric acid formation (APExBIO). The compound is supplied at 98% purity, verified by HPLC and NMR, and is insoluble in water and ethanol, but dissolves at ≥17.27 mg/mL in DMSO. Its antiulcer and antisecretory activities position it as a reference molecule for gastric acid secretion research and peptic ulcer disease models (summary). Data-driven protocols enable reproducible experiments in proton pump inhibition pathways (atomic dossier).

Biological Rationale

Gastric acid secretion is regulated primarily by the H+,K+-ATPase enzyme, the proton pump located in gastric parietal cells. Dysregulated proton pump activity is central to the pathophysiology of peptic ulcer disease and gastroesophageal reflux. Pharmacological inhibition of H+,K+-ATPase remains a validated strategy for controlling excessive gastric acid output and supporting mucosal healing (Kong et al., 2025). 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is engineered to provide robust, specific blockade of this pathway, facilitating mechanistic studies and model validation in gastric acid-related disorders (see mechanistic review).

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

This compound acts as a competitive inhibitor of H+,K+-ATPase, binding the enzyme and preventing ATP-driven proton translocation into the gastric lumen. The IC50 for direct inhibition is 5.8 μM under standard biochemical assay conditions (25°C, buffer pH 7.4) (APExBIO). In cell-based assays, it suppresses histamine-induced gastric acid secretion with an IC50 of 0.16 μM, demonstrating high potency. The molecular structure (C17H19N3O3S; 345.42 g/mol) confers selectivity and oral bioavailability in preclinical settings. Its action on the proton pump is distinct from histamine H2 receptor antagonists, as it directly targets the terminal acid secretion step (see potency analysis).

Evidence & Benchmarks

• Demonstrates H+,K+-ATPase inhibition with an IC50 of 5.8 μM in in vitro enzyme assays (APExBIO, product data).
• Exhibits sub-micromolar activity (IC50 = 0.16 μM) against histamine-stimulated gastric acid formation in cell-based models (internal summary).
• Validated at 98% purity by HPLC and NMR, ensuring reproducibility in research workflows (APExBIO, certificate of analysis).
• Solubility in DMSO is ≥17.27 mg/mL, permitting high-concentration stock solutions for precise dosing (solubility protocols).
• Recommended for antiulcer and gastric acid secretion research, not for diagnostic or clinical use (APExBIO, product terms).
• Does not alter cytokine levels or neuroinflammation endpoints outside gastric models; see Kong et al., 2025 for related negative controls (DOI).

Applications, Limits & Misconceptions

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is optimized for preclinical research in gastric acid secretion, proton pump inhibition, and antiulcer model development. Its defined potency and selectivity support benchmarking in peptic ulcer disease models and comparative drug screening. However, it is not validated for neuroinflammation studies or as a diagnostic agent. The compound is unsuitable for use in living organisms outside controlled laboratory protocols and is not intended for therapeutic or diagnostic applications in humans (APExBIO).

Common Pitfalls or Misconceptions

• Not suitable for long-term storage in solution; solid form at -20°C is strongly recommended to preserve potency.
• Not soluble in water or ethanol; use only DMSO for stock solutions.
• Does not inhibit H2 receptors or other upstream secretagogues; its effect is limited to the H+,K+-ATPase terminal step.
• Not validated for neuroinflammation or gut–brain axis studies; its action is specific to gastric acid pathways.
• For research use only; not for use in diagnostic or therapeutic procedures.

Workflow Integration & Parameters

For optimal experimental use, dissolve the compound in DMSO to achieve working concentrations (stock: 10–20 mM). Avoid aqueous or alcoholic solvents. Store solid at -20°C; minimize freeze-thaw cycles. For in vitro assays, typical working concentrations range from 0.01 μM to 10 μM, depending on the pathway and cell type. Analytical verification by HPLC and NMR ensures batch-to-batch consistency. For protocols and troubleshooting, see this advanced workflow guide, which provides practical steps and addresses common errors not detailed here. This article extends previous discussions by including solubility, purity, and stability data for translational applications.

Conclusion & Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide from APExBIO provides a robust, validated tool for gastric acid secretion and antiulcer research. Its atomic data, precise benchmarks, and defined workflow parameters help ensure reproducibility and facilitate next-generation studies in proton pump inhibition. For further mechanistic insights and translational opportunities, see our review on neuro-gastric intersections, which this article updates by providing the latest stability and solubility findings. Researchers should note its boundaries and optimal handling to maximize experimental reliability.